PT - JOURNAL ARTICLE AU - Rodda, Lauren B. AU - Netland, Jason AU - Shehata, Laila AU - Pruner, Kurt B. AU - Morawski, Peter A. AU - Thouvenel, Chris AU - Takehara, Kennidy K. AU - Eggenberger, Julie AU - Hemann, Emily A. AU - Waterman, Hayley R. AU - Fahning, Mitchell L. AU - Chen, Yu AU - Rathe, Jennifer AU - Stokes, Caleb AU - Wrenn, Samuel AU - Fiala, Brooke AU - Carter, Lauren AU - Hamerman, Jessica A. AU - King, Neil P. AU - Gale, Michael AU - Campbell, Daniel J. AU - Rawlings, David AU - Pepper, Marion TI - Functional SARS-CoV-2-specific immune memory persists after mild COVID-19 AID - 10.1101/2020.08.11.20171843 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.11.20171843 4099 - http://medrxiv.org/content/early/2020/08/15/2020.08.11.20171843.short 4100 - http://medrxiv.org/content/early/2020/08/15/2020.08.11.20171843.full AB - The recently emerged SARS-CoV-2 virus is currently causing a global pandemic and cases continue to rise. The majority of infected individuals experience mildly symptomatic coronavirus disease 2019 (COVID-19), but it is unknown whether this can induce persistent immune memory that might contribute to herd immunity. Thus, we performed a longitudinal assessment of individuals recovered from mildly symptomatic COVID-19 to determine if they develop and sustain immunological memory against the virus. We found that recovered individuals developed SARS-CoV-2-specific IgG antibody and neutralizing plasma, as well as virus-specific memory B and T cells that not only persisted, but in some cases increased numerically over three months following symptom onset. Furthermore, the SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral immunity: memory T cells secreted IFN-γ and expanded upon antigen re-encounter, while memory B cells expressed receptors capable of neutralizing virus when expressed as antibodies. These findings demonstrate that mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks associated with antiviral protective immunity.Competing Interest StatementM.P., D.R., J.N., C.T., Y.C. and L.B.R. have filed a patent under the provisional serial no. 63/063,841. Other authors declare no competing interests.Funding StatementThis work was supported by the following funding: L.B.R and L.S (NIH2T32 AI106677), D.J.C. and P.M. (NIH R01AI127726, NIH U19AI125378-S1), J.A.H. (NIH R01AI150178-01S1), H.R.W. (NIH TL1 TR002318), D.R. (SCRI, Research Integration Hub Covid-19 Award), M.P. (NIH U01AI142001-02S1; R01AI118803); a Bill & Melinda Gates Foundation grant to N.P.K. (OPP1156262); BWF #1018486 and COVID Pilot grant to M.P.; Emergent Ventures Fast Grant to M.P. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Washington Institutional Review Board (Gale Lab, IRB 00009810).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this published article (and its supplementary information files) or available from the corresponding author upon reasonable request.